Table 4.
Impact of positive status for High-14-3-3η, rheumatoid factor (RF), anticyclic peptide antibodies (ACPA) and high C-reactive protein (CRP) at each visit on prediction of rapid erosive progression (REP) according to low (<5) (table 4A) or high Sharp Erosion Score (≥5) (table 4B) at a given visit
| Visits | REP (ΔErosions ≥5 between 2 consecutive visits) | |||
|---|---|---|---|---|
| Total | n (%) | RR (95% CI) | P value | |
| A | ||||
| Non-erosive status at the visit (Sharp Erosion Score <5) | ||||
| Individual variables | ||||
| 14-3-3η | 437 | 37 (8.5) | 2.78 (1.75–4.4) | <0.0001 |
| ACPA positive | 457 | 41 (9) | 3.64 (2.19–6.03) | <0.0001 |
| RF positive | 461 | 40 (8.7) | 3.19 (1.98–5.14) | <0.0001 |
| CRP | 485 | 46 (9.5) | 4.31 (2.65–7.01) | <0.0001 |
| RF, ACPA | (n=1388) | |||
| Both negative | 816 | 16 (2) | 1 | |
| One positive | 264 | 17 (6.4) | 3.29 (1.69–6.39) | 0.0005 |
| Both positive | 308 | 31 (10.1) | 5.1 (2.81–9.26) | <0.0001 |
| RF, CRP | (n=1505) | |||
| Both negative | 725 | 12 (1.7) | 1 | |
| One positive | 615 | 26 (4.2) | 2.52 (1.3–4.87) | 0.0062 |
| Both positive | 165 | 30 (18.2) | 10.62 (5.56–20.3) | <0.0001 |
| ACPA, CRP | (n=1392) | |||
| Both negative | 636 | 8 (1.3) | 1 | |
| One positive | 601 | 28 (4.7) | 3.71 (1.74–7.93) | 0.0007 |
| Both positive | 155 | 28 (18.1) | 14.06 (6.62–29.85) | <0.0001 |
| 14-3-3η, RF | (n=1443) | |||
| Both negative | 796 | 21 (2.6) | 1 | |
| One positive | 416 | 15 (3.6) | 1.36 (0.72–2.56) | 0.347 |
| Both positive | 231 | 31 (13.4) | 4.99 (2.9–8.6) | <0.0001 |
| 14-3-3η, ACPA | (n=1335) | |||
| Both negative | 688 | 13 (1.9) | 1 | |
| One positive | 454 | 25 (5.5) | 2.88 (1.51–5.51) | 0.0014 |
| Both positive | 193 | 25 (13) | 6.75 (3.51–12.96) | <0.0001 |
| 14-3-3η, CRP | (n=1446) | |||
| Both negative | 682 | 15 (2.2) | 1 | |
| One positive | 624 | 22 (3.5) | 1.58 (0.84–2.98) | 0.1567 |
| Both positive | 140 | 30 (21.4) | 9.41 (5.25–16.86) | <0.0001 |
| 14-3-3η, RF, CRP | (n=1443) | |||
| All negative | 540 | 12 (2.2) | 1 | |
| One positive | 544 | 12 (2.2) | 0.99 (0.45–2.16) | 0.9814 |
| Two positive | 275 | 19 (6.9) | 3.07 (1.53–6.17) | 0.0016 |
| All positive | 84 | 24 (28.6) | 12.47 (6.47–24.03) | <0.0001 |
| 14-3-3η, ACPA, CRP | (n=1334) | |||
| All negative | 456 | 6 (1.3) | 1 | |
| One positive | 547 | 18 (3.3) | 2.48 (1.01–6.06) | 0.0464 |
| Two positive | 260 | 18 (6.9) | 5.21 (2.13–12.75) | 0.0003 |
| All positive | 71 | 21 (29.6) | 21.85 (9.3–51.34) | <0.0001 |
| 14-3-3η, RF, ACPA | (n=1331) | |||
| All negative | 627 | 13 (2.1) | 1 | |
| One positive | 317 | 9 (2.8) | 1.37 (0.6–3.11) | 0.4504 |
| Two positive | 233 | 19 (8.2) | 3.91 (1.96–7.79) | 0.0001 |
| All positive | 154 | 22 (14.3) | 6.81 (3.49–13.3) | <0.0001 |
| RF, ACPA, CRP | (n=1388) | |||
| All negative | 552 | 6 (1.1) | 1 | |
| One positive | 457 | 18 (3.9) | 3.61 (1.48–8.79) | 0.0047 |
| Two positive | 260 | 16 (6.2) | 5.7 (2.29–14.17) | 0.0002 |
| All positive | 119 | 24 (20.2) | 18.11 (7.7–42.61) | <0.0001 |
| 14-3-3η, RF, ACPA, CRP | (n=1331) | |||
| All negative | 411 | 6 (1.5) | 1 | |
| One positive | 450 | 13 (2.9) | 1.96 (0.77–5.02) | 0.158 |
| Two positive | 234 | 8 (3.4) | 2.34 (0.85–6.5) | 0.1015 |
| Three positive | 176 | 18 (10.2) | 6.95 (2.83–17.03) | <0.0001 |
| All positive | 60 | 18 (30) | 19.99 (8.39–47.64) | <0.0001 |
| B | ||||
| Erosive status at the visit (Sharp Erosion Score ≥5) | ||||
| Individual variables | ||||
| 14-3-3η | 258 | 52 (20.2) | 1.08 (0.75–1.55) | 0.6827 |
| ACPA positive | 270 | 62 (22.3) | 1.6 (1.06–2.42) | 0.0245 |
| RF positive | 301 | 75 (24.9) | 1.93 (1.31–2.84) | 0.0009 |
| CRP | 236 | 62 (26.3) | 1.67 (1.19–2.34) | 0.0029 |
| RF, ACPA | (n=550) | |||
| Both negative | 243 | 29 (11.9) | 1 | |
| One positive | 89 | 18 (20.2) | 1.48 (0.79–2.74) | 0.2192 |
| Both positive | 218 | 54 (24.8) | 2.09 (1.3–3.35) | 0.0022 |
| RF, CRP | (n=650) | |||
| Both negative | 232 | 20 (8.6) | 1 | |
| One positive | 302 | 59 (19.5) | 2 (1.25–3.2) | 0.004 |
| Both positive | 116 | 39 (33.6) | 3.17 (1.87–5.35) | <0.0001 |
| ACPA, CRP | (n=553) | |||
| Both negative | 186 | 20 (10.8) | 1 | |
| One positive | 263 | 46 (17.5) | 1.58 (1.05–2.37) | 0.0299 |
| Both positive | 104 | 35 (33.7) | 2.58 (1.57–4.26) | 0.0002 |
| 14-3-3η, RF | (n=640) | |||
| Both negative | 274 | 40 (14.6) | 1 | |
| One positive | 177 | 29 (16.4) | 1.32 (0.85–2.06) | 0.2145 |
| Both positive | 189 | 49 (25.9) | 1.65 (1.04–2.64) | 0.0344 |
| 14-3-3η, ACPA | (n=546) | |||
| Both negative | 215 | 31 (14.4) | 1 | |
| One positive | 173 | 34 (19.7) | 1.26 (0.84–1.88) | 0.2667 |
| Both positive | 158 | 36 (22.8) | 1.45 (0.91–2.33) | 0.1204 |
| 14-3-3η, CRP | (n=644) | |||
| Both negative | 253 | 33 (13) | 1 | |
| One positive | 290 | 56 (19.3) | 1.28 (0.86–1.89) | 0.2222 |
| Both positive | 101 | 29 (28.7) | 1.85 (1.19–2.89) | 0.0063 |
| 14-3-3η, RF, CRP | (n=640) | |||
| All negative | 181 | 19 (10.5) | 1 | |
| One positive | 208 | 36 (17.3) | 1.64 (0.95–2.84) | 0.0784 |
| Two positive | 174 | 36 (20.7) | 1.83 (1.05–3.19) | 0.0316 |
| All positive | 77 | 27 (35.1) | 2.86 (1.58–5.19) | 0.0005 |
| 14-3-3η, ACPA, CRP | (n=546) | |||
| All negative | 137 | 15 (10.9) | 1 | |
| One positive | 198 | 35 (17.7) | 1.45 (0.95–2.23) | 0.0875 |
| Two positive | 141 | 28 (19.9) | 1.69 (0.99–2.87) | 0.0535 |
| All positive | 70 | 23 (32.9) | 2.42 (1.4–4.21) | 0.0017 |
| 14-3-3η, RF, ACPA | (n=543) | |||
| All negative | 195 | 27 (13.8) | 1 | |
| One positive | 94 | 13 (13.8) | 1.02 (0.55–1.91) | 0.9491 |
| Two positive | 114 | 26 (22.8) | 1.69 (0.97–2.92) | 0.0625 |
| All positive | 140 | 35 (25) | 1.78 (1.05–3.03) | 0.0336 |
| RF, ACPA, CRP | (n=550) | |||
| All negative | 161 | 13 (8.1) | 1 | |
| One positive | 140 | 28 (20) | 1.94 (1.18–3.19) | 0.0091 |
| Two positive | 162 | 28 (17.3) | 2.16 (1.25–3.72) | 0.0055 |
| All positive | 87 | 32 (36.8) | 3.65 (2.1–6.37) | <0.0001 |
| 14-3-3η, RF, ACPA, CRP | (n=543) | |||
| All negative | 126 | 12 (9.5) | 1 | |
| One positive | 133 | 24 (18) | 1.63 (0.94–2.84) | 0.0847 |
| Two positive | 105 | 17 (16.2) | 1.71 (0.93–3.14) | 0.0841 |
| Three positive | 117 | 26 (22.2) | 2.22 (1.2–4.1) | 0.0111 |
| All positive | 62 | 22 (35.5) | 3.07 (1.64–5.75) | 0.0005 |